The spliceosome as a new therapeutic vulnerability in aggressive prostate cancer

Cheng Zou; Dingxiao Zhang

doi:10.1080/23723556.2020.1778420

The spliceosome as a new therapeutic vulnerability in aggressive prostate cancer

Mol Cell Oncol. 2020 Jun 18;7(5):1778420. doi: 10.1080/23723556.2020.1778420. eCollection 2020.

Authors

Cheng Zou¹, Dingxiao Zhang¹

Affiliation

¹ College of Biology, Hunan University, Changsha, China.

Abstract

Alternative splicing (AS) analysis across the entire spectrum of human prostate cancer evolution reveals the unexpected findings that intron retention is a hallmark of stemness and tumor aggressiveness, and androgen receptor controls a splicing program distinct from its transcriptional regulation. Importantly, twisted activity of the spliceosome causing abnormal AS landscape represents a therapeutic vulnerability in aggressive prostate cancer.

Keywords: Alternative splicing; CRPC; E7107; cancer treatment; prostate cancer; spliceosome.

Grants and funding

This work was supported by the National Natural Science Foundation of China [81972418] and Wuhan Municipal Science and Technology Bureau (CN) [2019020701011490].